Verhoeff N P, Sokole E B, Stabin M, Hengst D, Kung H F, Van Royen E A, Janssen A G
Department of Nuclear Medicine, Academic Medical Centre, Amsterdam, The Netherlands.
Eur J Nucl Med. 1993 Sep;20(9):747-52. doi: 10.1007/BF00180903.
The distribution of the dopamine D2-receptor specific ligand iodine-123 (S)-(-)-2-hydroxy-3-iodo-6-methoxy-N[(1-ethyl-2- pyrrolidinyl)methyl]-benzamide (123I-IBZM) was investigated in human adults from whole-body scans, blood samples and urine collected up to 48 h after injection. Results from the present study performed in six healthy volunteers were combined with those of five volunteers from a previous study. Using the brain, liver, lungs and spleen as source organs, the MIRD method was applied to calculate the absorbed radiation dose of the radioligand in various organs. The thyroid (despite blockage), gallbladder wall, large intestinal walls and spleen received the highest absorbed doses. The average effective dose equivalent of 123I-IBZM for adults was estimated to be 0.034 mSv/MBq. The absorbed dose to the thyroid may be a limiting factor for 123I-IBZM studies in children.
通过全身扫描、血液样本以及注射后48小时内收集的尿液,对多巴胺D2受体特异性配体碘-123(S)-(-)-2-羟基-3-碘-6-甲氧基-N-[(1-乙基-2-吡咯烷基)甲基]-苯甲酰胺(123I-IBZM)在成年人体内的分布情况进行了研究。本研究中六名健康志愿者的结果与先前研究中五名志愿者的结果相结合。以脑、肝、肺和脾作为源器官,应用MIRD方法计算放射性配体在各个器官中的吸收辐射剂量。甲状腺(尽管已进行阻断)、胆囊壁、大肠壁和脾接受的吸收剂量最高。估计123I-IBZM对成年人的平均有效剂量当量为0.034 mSv/MBq。甲状腺的吸收剂量可能是123I-IBZM在儿童研究中的一个限制因素。